Hypotaurine Blocks Glucose-Driven Arterial Calcification in Diabetic Vessels
A multi-omics study reveals hypotaurine suppresses vascular calcification triggered by high glucose, pointing to a novel therapeutic target in diabetes.
Summary
Researchers used untargeted metabolomics and transcriptomics to investigate how high blood sugar drives vascular calcification (VC) in smooth muscle cells (SMCs). They found that glucose promotes calcification in a dose- and time-dependent manner, and that the hypotaurine/taurine metabolic pathway sits at the center of this process. Blocking hypotaurine production worsened calcification, while adding hypotaurine directly prevented it. High glucose also altered mitochondrial energy metabolism in calcifying SMCs, and hypotaurine partially restored oxygen consumption. A murine warfarin model validated the findings, showing reduced expression of the hypotaurine/taurine transporter in SMCs. These results identify hypotaurine as a promising therapeutic candidate against diabetes-related arterial calcification.
Detailed Summary
Vascular calcification (VC) is a serious and currently untreatable complication of type 2 diabetes mellitus (T2DM) and chronic kidney disease. It involves mineral deposition in arterial walls, causing stiffening, plaque vulnerability, and heart failure. Despite a well-established clinical link between hyperglycemia and VC, the underlying molecular mechanisms remain poorly understood. This study set out to systematically characterize how elevated glucose drives calcification in vascular smooth muscle cells (SMCs) using a comprehensive multi-omics approach.
Human primary and immortalized coronary artery SMCs were cultured under three glucose concentrations (0, 5.5, and 25 mM) in calcifying (calcium/phosphate-enriched) media. Untargeted intracellular and extracellular metabolomics, RNA transcriptomics, mitochondrial respiration (Seahorse analysis), and real-time live-cell imaging were performed at multiple time points. Alizarin Red S staining and Fetuin-A fluorescent probes tracked extracellular matrix (ECM) mineralization. A murine warfarin-induced calcification model provided in vivo validation.
Glucose promoted ECM calcification in a concentration- and time-dependent manner. Strikingly, total absence of glucose abolished calcification entirely, but also significantly reduced SMC proliferation, suggesting glucose is both a metabolic fuel and a calcification driver. Multi-omics data integration—combining transcriptomic and metabolomic layers—identified the hypotaurine/taurine metabolic pathway as the central hub of a reconstructed regulatory network. High glucose increased extracellular secretion of hypotaurine, while intracellular hypotaurine levels were not significantly changed, suggesting enhanced efflux rather than altered synthesis. Pharmacological inhibition of hypotaurine production using propargylglycine (PAG) aggravated ECM calcification, while exogenous hypotaurine treatment dose-dependently reduced it. siRNA-mediated knockdown of SLC6A6 (the taurine transporter, TAUT) further confirmed the pathway's relevance.
Energy metabolism was also disrupted in calcifying SMCs under hyperglycemia. Seahorse analysis revealed decreased mitochondrial oxygen consumption in calcifying SMCs, consistent with a shift away from oxidative phosphorylation. Importantly, hypotaurine treatment partially restored oxygen consumption rates, linking its anti-calcific effects to mitochondrial function. In the murine warfarin model of VC, TAUT expression was reduced in SMCs of calcified aortic arches compared to controls, supporting translational relevance of the pathway.
These findings collectively establish hypotaurine as an endogenous inhibitor of glucose-driven vascular calcification, acting at least partly through preservation of mitochondrial respiration. The study also highlights that glucose is not merely a bystander in VC but actively fuels the pathological process. While the work is primarily in vitro with one animal model for validation, it opens a compelling new avenue for therapeutic intervention in diabetic cardiovascular disease.
Key Findings
- High glucose promotes SMC extracellular matrix calcification in a concentration- and time-dependent manner.
- Multi-omics integration identified the hypotaurine/taurine pathway as the central regulatory hub in glucose-induced calcification.
- Exogenous hypotaurine dose-dependently prevented ECM calcification; blocking its production with propargylglycine worsened it.
- Calcifying SMCs under hyperglycemia showed reduced mitochondrial oxygen consumption, partially restored by hypotaurine.
- Murine warfarin calcification model showed reduced taurine transporter (TAUT/SLC6A6) expression in SMCs, validating findings in vivo.
Methodology
Human primary and immortalized coronary artery SMCs were cultured at 0, 5.5, and 25 mM glucose under calcium/phosphate calcifying conditions. Untargeted intra- and extracellular metabolomics and RNA transcriptomics were performed at multiple time points, integrated via network analysis. Mitochondrial function was assessed by Seahorse respirometry, and findings were validated in a murine warfarin-induced arterial calcification model.
Study Limitations
The study is primarily in vitro using cultured SMCs, limiting direct clinical translation; the murine warfarin model does not fully replicate diabetic hyperglycemia. Mechanistic details of how hypotaurine modulates mitochondrial function and ECM calcification remain incompletely defined. The study did not include diabetic animal models or human tissue from diabetic patients to directly validate glucose-specific effects in vivo.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: